Perseus Proteomics Full Year 2024 Earnings: JP¥93.65 loss per share (vs JP¥66.84 loss in FY 2023)
Perseus Proteomics (TSE:4882) Full Year 2024 Results
Key Financial Results
- Net loss: JP¥1.10b (loss widened by 41% from FY 2023).
- JP¥93.65 loss per share (further deteriorated from JP¥66.84 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Perseus Proteomics shares are down 10% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 5 warning signs for Perseus Proteomics (of which 3 are potentially serious!) you should know about.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About TSE:4882
Perseus Proteomics
A drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan.
Flawless balance sheet moderate.